| Pharmacogenomics—drug disposition, drug targets, and side effects WE Evans, HL McLeod New England Journal of Medicine 348 (6), 538-549, 2003 | 2234 | 2003 |
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ... New England Journal of Medicine 352 (22), 2285-2293, 2005 | 1656 | 2005 |
| Doxorubicin pathways: pharmacodynamics and adverse effects CF Thorn, C Oshiro, S Marsh, T Hernandez-Boussard, H McLeod, ... Pharmacogenetics and genomics 21 (7), 440, 2011 | 978 | 2011 |
| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ... Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008 | 829 | 2008 |
| Genomics and drug response L Wang, HL McLeod, RM Weinshilboum New England Journal of Medicine 364 (12), 1144-1153, 2011 | 619 | 2011 |
| MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity MM Ameyaw, F Regateiro, T Li, X Liu, M Tariq, A Mobarek, N Thornton, ... Pharmacogenetics and Genomics 11 (3), 217-221, 2001 | 559 | 2001 |
| Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer Y Wang, T Jatkoe, Y Zhang, MG Mutch, D Talantov, J Jiang, HL McLeod, ... Journal of clinical oncology 22 (9), 1564-1571, 2004 | 533 | 2004 |
| Platinum neurotoxicity pharmacogenetics SR McWhinney, RM Goldberg, HL McLeod Molecular cancer therapeutics 8 (1), 10-16, 2009 | 515 | 2009 |
| Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia HL McLeod, EY Krynetski, MV Relling, WE Evans Leukemia 14 (4), 567-572, 2000 | 505 | 2000 |
| UGT1A1* 28 genotype and irinotecan-induced neutropenia: dose matters JM Hoskins, RM Goldberg, P Qu, JG Ibrahim, HL McLeod Journal of the National Cancer Institute 99 (17), 1290-1295, 2007 | 503 | 2007 |
| Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs S Zhou, SY Chan, BC Goh, E Chan, W Duan, M Huang, HL McLeod Clinical pharmacokinetics 44 (3), 279-304, 2005 | 503 | 2005 |
| PI3K/Akt/mTOR pathway as a target for cancer therapy D Morgensztern, HL McLeod Anti-cancer drugs 16 (8), 797-803, 2005 | 466 | 2005 |
| Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine AJ Black, HL McLeod, HA Capell, RH Powrie, LK Matowe, SC Pritchard, ... Annals of internal medicine 129 (9), 716-718, 1998 | 452 | 1998 |
| Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. X Wei, HL McLeod, J McMurrough, FJ Gonzalez, P Fernandez-Salguero The Journal of clinical investigation 98 (3), 610-615, 1996 | 428 | 1996 |
| The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations ESR Collie-Duguid, J Sludden, T Li, HL McLeod Pharmacogenetics and Genomics 9 (1), 37-42, 1999 | 406 | 1999 |
| Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin BF Gage, C Eby, PE Milligan, GA Banet, JR Duncan, HL McLeod Thrombosis and haemostasis 91 (01), 87-94, 2004 | 404 | 2004 |
| Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism GJ Peters, HHJ Backus, S Freemantle, B Van Triest, G Codacci-Pisanelli, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002 | 388 | 2002 |
| PHARMACOGENOMICS: Unlocking the Human Genome for Better Drug Therapy HL McLeod, WE Evans Annual review of pharmacology and toxicology 41 (1), 101-121, 2001 | 380 | 2001 |
| Strategies for enzyme/prodrug cancer therapy G Xu, HL McLeod Clinical Cancer Research 7 (11), 3314-3324, 2001 | 361 | 2001 |
| Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations PB Ferrell, HL McLeod Future Medicine Ltd 9 (10), 1543-1546, 2008 | 358 | 2008 |
Teri E. KleinStanford UniversityVerified email at stanford.edu
